Vertex Pharmaceuticals (VRTX) Minority Interest (2011 - 2018)

Vertex Pharmaceuticals has reported Minority Interest for 8 years, with the latest figure at $28.4 million in Q3 2018.

• For the quarter ending Q3 2018, Minority Interest rose 133.13% year-over-year to $28.4 million; the trailing twelve-month figure through Sep 2018 stood at $28.4 million (up 133.13% YoY), and the FY2017 full-year result was $13.7 million, down 92.44% from the prior year.
• Minority Interest for Q3 2018 stood at $28.4 million, down from $28.7 million in the prior quarter.
• The five-year high for Minority Interest was $196.0 million in Q2 2017, with the low at $12.2 million in Q3 2017.
• Average Minority Interest over 5 years is $106.9 million, with a median of $153.5 million recorded in 2015.
• Year-over-year, Minority Interest surged 654.87% in 2016 and plunged 93.49% in 2017.
• Tracing VRTX's Minority Interest over 5 years: stood at $21.2 million in 2014, then jumped by 625.6% to $153.7 million in 2015, then climbed by 18.19% to $181.6 million in 2016, then plunged by 92.44% to $13.7 million in 2017, then jumped by 106.64% to $28.4 million in 2018.
• The last three Minority Interest figures came in at $28.4 million (Q3 2018), $28.7 million (Q2 2018), and $29.8 million (Q1 2018), per Business Quant data.

Peer Comparison